Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 10/20 | 0.63 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21776965 | 0.80 | NOTUM (0.60) | METAP2NOTUM | |
| SCHEMBL12170980 | 0.77 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2ADCY1 | |
| SCHEMBL21777038 | 0.77 | NOTUM (0.62) | METAP2NOTUM | |
| SCHEMBL3492339 | 0.77 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28723457 | 0.75 | GSK3A (0.62) | METAP2NPC1RAB9ASMN1; SMN2ADCY1 | |
| SCHEMBL30816136 | 0.75 | GSK3A (0.62) | METAP2NPC1RAB9ASMN1; SMN2ADCY1 | |
| SCHEMBL23451538 | 0.74 | NOTUM (0.57) | METAP2NOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12871205 | 0.74 | STIM1 (0.64) | NPC1RAB9ASMN1; SMN2ADCY1 | |
| SCHEMBL15677665 | 0.73 | ALOX5 (0.72) | NOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21776892 | 0.73 | NOTUM (0.61) | METAP2NOTUMNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | METAP2 1223/4885NOTUM 1/4885NPC1 51/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | METAP2 2776/4885NOTUM 5/4885NPC1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.